Advertiser / Brand
Johnson & Johnson vs Royal Philips
Structured technology and market comparison · 2026
Direct Feature Comparison
Johnson & Johnson · vs · Royal PhilipsLarge public healthcare manufacturer and commercial products company.
Dutch health technology company serving providers and consumers.
Analyze all overlapping signals and tech stacks for Johnson & Johnson and Royal Philips
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Johnson & Johnson and Royal Philips?
Johnson & Johnson operates as a diversified global healthcare giant, leveraging massive operating scale to deliver pharmaceuticals and medical technology. In contrast, Royal Philips concentrates specifically on health technology, systems, and connected clinical informatics. J&J targets broad medical markets through direct product sales, while Philips focuses on health systems, enterprise imaging, and connected care infrastructure for clinical providers.
How do the features of Johnson & Johnson and Royal Philips compare?
Johnson & Johnson delivers advanced medical devices, surgical instruments, and pharmacological therapeutics backed by extensive regulatory compliance. Royal Philips provides enterprise health informatics, diagnostic imaging hardware, patient monitoring systems, and lifecycle clinical support services. Technical overlap centers on hospital-grade medical hardware, though Philips emphasizes integrated software workflows and continuous patient monitoring architecture.
What are the top alternatives to Johnson & Johnson and Royal Philips?
When evaluating Johnson & Johnson and Royal Philips, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Johnson & Johnson and Royal Philips compare?
Johnson & Johnson is headquartered in US (founded in 1887) with >5,000 employees. Royal Philips is based in NL (founded in 1891) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Johnson & Johnson vs Royal Philips
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Johnson & Johnson
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Johnson & Johnson (2026-08-04)
On August 4, 2026, Johnson & Johnson filed a Form 8-K announcing the retirement of Jennifer Taubert from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026. This represents a significant leadership transition for Johnson & Johnson's core pharmaceutical and innovative medicine division, which accounts for a substantial portion of the company's global revenue and R&D pipeline.
- Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine, effective September 1, 2026.
- Taubert will simultaneously step down from her role as a member of Johnson & Johnson's Executive Committee.
- The announcement was formalized via Form 8-K under Item 5.02 on August 4, 2026.
- ·Johnson & Johnson
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
- ·Johnson & Johnson
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.
Royal Philips
Recent Signals
- ·SEC APIfinancials
6-K Financial Filing Analysis for Royal Philips (2026-07-28)
Koninklijke Philips N.V. reported solid Q2 2026 financial results with group sales reaching EUR 4.36 billion, reflecting 4% comparable sales growth driven by improvements across all business segments. Income from operations increased significantly to EUR 609 million and Adjusted EBITA rose to EUR 717 million (16.4% margin), bolstered by an effective 4.2% (EUR 186 million) benefit from US tariff refunds. Net income reached EUR 386 million, up from EUR 240 million in Q2 2025. Following the recovery of US import duties, Philips upgraded its full-year 2026 Adjusted EBITA margin outlook to 13.5%-14.0% (previously 12.5%-13.0%) and increased its Free Cash Flow guidance to EUR 1.5-1.7 billion (previously EUR 1.3-1.5 billion), while reiterating comparable sales growth guidance of 3.0%-4.5%.
- Q2 2026 sales reached EUR 4,360,000,000 (+4% comparable sales growth), with net income increasing 60.8% YoY to EUR 386,000,000.
- Adjusted EBITA increased to EUR 717,000,000 (16.4% margin), including a EUR 186,000,000 US tariff refund benefit.
- Full-year 2026 outlook updated: Adjusted EBITA margin raised to 13.5%-14.0% and Free Cash Flow raised to EUR 1.5-1.7 billion; comparable sales growth reaffirmed at 3%-4.5%.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Johnson & Johnson and Royal Philips share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks